Circulating Tumor DNA Detection in the Management of Anti-EGFR Therapy for Advanced Colorectal Cancer

The liquid biopsy in the management of colorectal cancer patients: current applications and future scenarios

(2018) Nicola Normanno et al.   CANCER TREATMENT REVIEWS

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review

(2018) Jason D. Merker et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge

(2018) C M Parseghian et al.   ANNALS OF ONCOLOGY

Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC

(2017) Franciele H. Knebel et al.   LUNG CANCER

Blood-based detection ofRASmutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-basedRAStesting

(2017) Wolff Schmiegel et al.   Molecular Oncology

Integrating liquid biopsies into the management of cancer

(2017) Giulia Siravegna et al.   Nature Reviews Clinical Oncology

Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer

(2016) Filippo Pietrantonio et al.   CLINICAL CANCER RESEARCH

Mechanisms of resistance to anti-EGFR therapy in colorectal cancer

(2016) Ben Zhao et al.   Oncotarget

First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405

(2015) Elena Elez et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer

(2015) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

(2015) Giulia Siravegna et al.   NATURE MEDICINE

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

(2014) Volker Heinemann et al.   LANCET ONCOLOGY

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

(2012) Luis A. Diaz Jr et al.   NATURE

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE